Ucb
UCB, or UCB S.A., is a global biopharmaceutical company headquartered in Belgium. Founded in 1928, UCB has established itself as a leader in the biopharmaceutical industry, focusing on the development of innovative therapies for neurological and immunological disorders. With a strong presence in Europe and North America, UCB is dedicated to improving the lives of patients through its core products, including treatments for epilepsy, Parkinson's disease, and autoimmune conditions. The company is renowned for its commitment to research and development, which has led to significant milestones such as the launch of several groundbreaking therapies. UCB's unique approach combines advanced science with patient-centric solutions, positioning it as a key player in the global healthcare market. With a robust pipeline and a focus on unmet medical needs, UCB continues to make notable strides in the biopharmaceutical landscape.
DitchCarbon Score
How does Ucb's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ucb's score of 80 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Ucb's reported carbon emissions
In 2023, UCB reported total carbon emissions of approximately 63,165,000 kg CO2e, comprising 20,547,000 kg CO2e from Scope 1, 17,867,000 kg CO2e from Scope 2, and 63,165,000 kg CO2e from Scope 3 emissions. This reflects a commitment to reducing its carbon footprint significantly. UCB has set ambitious near-term targets to achieve a 73% reduction in absolute Scope 1 and 2 greenhouse gas emissions by 2030, using 2019 as the baseline year. Additionally, the company aims for a 48% reduction in absolute Scope 3 emissions within the same timeframe. Long-term, UCB is committed to reaching net-zero greenhouse gas emissions across its entire value chain by 2045. This includes a 90% reduction in both Scope 1 and 2 emissions and a similar 90% reduction in Scope 3 emissions by 2045, again using 2019 as the baseline. UCB also plans to ensure that 80% of its suppliers, based on emissions from purchased goods and services, will have science-based targets by 2028. UCB's climate commitments align with industry standards and reflect a proactive approach to addressing climate change, demonstrating leadership in the pharmaceuticals, biotechnology, and life sciences sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 44,059,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 5,316,000 | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 00,000,000 | 0,000 |
| Scope 3 | 568,003,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Ucb is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
